FDA approves AstraZeneca's Baxfendy, first-in-class drug for tough-to-treat hypertension

The U.S. Food and Drug Administration approved AstraZeneca's Baxfendy (baxdrostat) on May 18, 2026, making it the first aldosterone synthase inhibitor cleared for adults with hypertension. The drug targets a hormone pathway that drives stubborn high blood pressure in patients who don't respond well to existing therapies.

Hypertension affects roughly half of American adults and remains a leading risk factor for heart attacks, strokes and kidney failure. Standard treatments such as ACE inhibitors, diuretics and calcium channel blockers work for many patients, but a sizeable share continue to have elevated readings even on multiple drugs. Baxdrostat is designed for that group by blocking the enzyme that produces aldosterone, a hormone that signals the body to retain sodium and water.

In late-stage trials, AstraZeneca reported meaningful reductions in systolic blood pressure when baxdrostat was added to existing regimens, with a safety profile that allowed regulators to approve it without restrictive boxed warnings. Analysts had long flagged the program as one of the company's most important near-term launches in cardiovascular medicine.

Clinicians caution that real-world performance will depend on patient adherence, monitoring for changes in potassium and sodium levels, and access through insurance formularies. The approval also arrives amid leadership changes at the FDA's drug and biologics centers, which industry watchers say could affect the pace of future cardiovascular reviews.

Even so, the green light marks the first new mechanism for blood pressure control to reach the U.S. market in years, and it gives physicians an additional tool for one of the most common chronic conditions in medicine.